Immune phenotype in children with therapy-naïve remitted and relapsed Crohn’s disease

Table 1 Clinical data and patient characteristics

	Control	Therapy-naïve (before conventional therapy)	First remission (with conventional therapy)	Relapse (before IFX therapy)	IFX therapy (before 2nd infusion)	IFX therapy (before 3rd infusion)
Clinical data
n (boys/girls)	15 (6/9)	14 (6/8)	10 (4/6)	12 (5/7)
Age (yr)	12 (8-16)	10 (8.5-13)	11.5 (9.5-15.5)	14 (11-16)	14.5 (11.5-16)	14.5 (12-16)
Body mass index (kg/m2)	19.5 (16.5-22.3)	13.9 (12.5-15.8)d	18.6 (14.4-19.2)c	17.4 (14.1-19.5)a	18.8 (14.6-21.3)	19.25 (16.1-22.1)
Body weight (percentile)	58 (35-79)	13 (4-23)d	24 (19-44)c	21 (7-28)a	23 (15-63)	35 (10-74)
Disease duration (mo)	-	10 (8.5-13)	10.5 (8.5-15.5)	11.5 (9.25-15)	12 (9.5-15)	12 (10-15)
Activity index (PCDAI)	-	45 (39-58)	0 (0-5)f	45 (25-48)j	20 (7-28)g	13 (2-22)l
Localization (n, montreal criteria)	-	L1 (1), L2 (2), L3 (11)	L1 (0), L2 (2), L3 (8)	L1 (1), L2 (2), L3 (9)
Laboratory data
White blood cell count (g/L)	7.9 (5.7-10.1)	12.4 (9.4-14.2)b	11.7 (8.4-14.4)	10 (8.2-11.2)	7.9 (5.5-10.6)	6.7 (4.5-10.4)e
Platelet (g/L)	346 (288-375)	657 (451-746)b	442 (308-624)	479 (396-750)b	392 (293-523)	383 (308-483)e
Serum iron (μmol/L)	16 (14-21)	4 (2-12)a	8 (4-10)a	4 (2-7)d	5 (4-7)d	8 (6-8)be
Serum albumin (g/L)	45 (44-49)	37 (34-39)d	42 (42-45)c	40 (36-41)d	41 (38-45)b	42 (38-45)b
C-reactive protein (mg/L)	0 (0-1)	21 (5-65)d	7 (2-11)bc	27 (9-55)h, d	9 (3-11)d	5 (1-14)de

^aP < 0.05,

^bP < 0.01;

^dP < 0.01 vs control;

^cP < 0.05,

^fP < 0.01 vs therapy-naïve;

^hP < 0.01,

^jP < 0.01 vs first remission;

^eP < 0.05,

^gP < 0.05,

^lP < 0.001 vs relapse. IFX: Infliximab; PCDAI: Pediatric Crohn's disease activity index; L1: Small bowel; L2: Large bowel; L3: Small bowel and large bowel localization according to Montreal criteria[48].